Mana Capital Acquisition (MAAQ) Competitors

$1.88 +0.09 (+5.03%)

As of 05/1/2026

MAAQ vs. GRML, CUE, SCLX, MGX, and HYFT

Should you be buying Mana Capital Acquisition stock or one of its competitors? The main competitors of Mana Capital Acquisition include Greenland Mines Ltd. Common Stock (GRML), Cue Biopharma (CUE), Scilex (SCLX), Metagenomi (MGX), and MindWalk (HYFT). These companies are all part of the "pharmaceutical products" industry.

How does Mana Capital Acquisition compare to Greenland Mines Ltd. Common Stock?

Mana Capital Acquisition (NASDAQ:MAAQ) and Greenland Mines Ltd. Common Stock (NASDAQ:GRML) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mana Capital Acquisition N/A N/A N/A N/A N/A
Greenland Mines Ltd. Common Stock N/A N/A -$10.55M -$0.32 N/A
: Mana Capital Acquisition's return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity.
Company Net Margins Return on Equity Return on Assets
Mana Capital Acquisition N/A N/A N/A
Greenland Mines Ltd. Common Stock N/A -137.58% -126.00%
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mana Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Greenland Mines Ltd. Common Stock
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, Greenland Mines Ltd. Common Stock had 3 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 3 mentions for Greenland Mines Ltd. Common Stock and 0 mentions for Mana Capital Acquisition. Mana Capital Acquisition's average media sentiment score of 0.00 beat Greenland Mines Ltd. Common Stock's score of 0.00 indicating that Mana Capital Acquisition is being referred to more favorably in the media.
Company Overall Sentiment
Mana Capital Acquisition Neutral
Greenland Mines Ltd. Common Stock Neutral
: 68.4% of Mana Capital Acquisition shares are owned by institutional investors. Comparatively, 20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. 9.9% of Greenland Mines Ltd. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A

Company	Net Margins	Return on Equity	Return on Assets
Mana Capital Acquisition	N/A	N/A	N/A
Greenland Mines Ltd. Common Stock	N/A	-137.58%	-126.00%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
Mana Capital Acquisition	Neutral
Greenland Mines Ltd. Common Stock	Neutral

Summary

Mana Capital Acquisition beats Greenland Mines Ltd. Common Stock on 4 of the 7 factors compared between the two stocks.

How does Mana Capital Acquisition compare to Cue Biopharma?

Mana Capital Acquisition (NASDAQ:MAAQ) and Cue Biopharma (NASDAQ:CUE) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

: Mana Capital Acquisition has higher earnings, but lower revenue than Cue Biopharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mana Capital Acquisition N/A N/A N/A N/A N/A
Cue Biopharma $27.47M 4.12 -$26.60M -$9.61 N/A
: Mana Capital Acquisition has a net margin of 0.00% compared to Cue Biopharma's net margin of -96.85%. Mana Capital Acquisition's return on equity of 0.00% beat Cue Biopharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Mana Capital Acquisition N/A N/A N/A
Cue Biopharma -96.85% -165.19% -77.77%
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mana Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Cue Biopharma
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, Cue Biopharma had 8 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 8 mentions for Cue Biopharma and 0 mentions for Mana Capital Acquisition. Cue Biopharma's average media sentiment score of 0.29 beat Mana Capital Acquisition's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media.
Company Overall Sentiment
Mana Capital Acquisition Neutral
Cue Biopharma Neutral
: 68.4% of Mana Capital Acquisition shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 1.8% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Cue Biopharma	$27.47M	4.12	-$26.60M	-$9.61	N/A

Company	Net Margins	Return on Equity	Return on Assets
Mana Capital Acquisition	N/A	N/A	N/A
Cue Biopharma	-96.85%	-165.19%	-77.77%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
Mana Capital Acquisition	Neutral
Cue Biopharma	Neutral

Summary

Cue Biopharma beats Mana Capital Acquisition on 5 of the 9 factors compared between the two stocks.

How does Mana Capital Acquisition compare to Scilex?

Scilex (NASDAQ:SCLX) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scilex
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Mana Capital Acquisition
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 69.7% of Scilex shares are held by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are held by institutional investors. 4.1% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Mana Capital Acquisition has lower revenue, but higher earnings than Scilex.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Scilex $30.25M 3.01 -$358.73M -$36.45 N/A
Mana Capital Acquisition N/A N/A N/A N/A N/A
: Mana Capital Acquisition has a net margin of 0.00% compared to Scilex's net margin of -1,185.78%.
Company Net Margins Return on Equity Return on Assets
Scilex -1,185.78% N/A -178.57%
Mana Capital Acquisition N/A N/A N/A
: In the previous week, Scilex had 9 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 9 mentions for Scilex and 0 mentions for Mana Capital Acquisition. Scilex's average media sentiment score of 0.94 beat Mana Capital Acquisition's score of 0.00 indicating that Scilex is being referred to more favorably in the media.
Company Overall Sentiment
Scilex Positive
Mana Capital Acquisition Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	3.01	-$358.73M	-$36.45	N/A
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,185.78%	N/A	-178.57%
Mana Capital Acquisition	N/A	N/A	N/A

Company	Overall Sentiment
Scilex	Positive
Mana Capital Acquisition	Neutral

Summary

Scilex beats Mana Capital Acquisition on 6 of the 8 factors compared between the two stocks.

How does Mana Capital Acquisition compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

: Mana Capital Acquisition has a net margin of 0.00% compared to Metagenomi's net margin of -348.54%. Mana Capital Acquisition's return on equity of 0.00% beat Metagenomi's return on equity.
Company Net Margins Return on Equity Return on Assets
Metagenomi -348.54% -47.14% -33.82%
Mana Capital Acquisition N/A N/A N/A
: In the previous week, Metagenomi had 1 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 1 mentions for Metagenomi and 0 mentions for Mana Capital Acquisition. Metagenomi's average media sentiment score of 0.00 equaled Mana Capital Acquisition'saverage media sentiment score.
Company Overall Sentiment
Metagenomi Neutral
Mana Capital Acquisition Neutral
: 68.4% of Mana Capital Acquisition shares are owned by institutional investors. 17.8% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: Mana Capital Acquisition has lower revenue, but higher earnings than Metagenomi.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Metagenomi $25.21M 2.11 -$87.87M -$2.37 N/A
Mana Capital Acquisition N/A N/A N/A N/A N/A
: Metagenomi presently has a consensus price target of $10.00, suggesting a potential upside of 609.22%. Given Metagenomi's stronger consensus rating and higher possible upside, research analysts plainly believe Metagenomi is more favorable than Mana Capital Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Metagenomi
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.80
Mana Capital Acquisition
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-348.54%	-47.14%	-33.82%
Mana Capital Acquisition	N/A	N/A	N/A

Company	Overall Sentiment
Metagenomi	Neutral
Mana Capital Acquisition	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	2.11	-$87.87M	-$2.37	N/A
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Metagenomi beats Mana Capital Acquisition on 7 of the 11 factors compared between the two stocks.

How does Mana Capital Acquisition compare to MindWalk?

MindWalk (NASDAQ:HYFT) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

: Mana Capital Acquisition has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. Mana Capital Acquisition's return on equity of 0.00% beat MindWalk's return on equity.
Company Net Margins Return on Equity Return on Assets
MindWalk -66.79% -69.37% -39.74%
Mana Capital Acquisition N/A N/A N/A
: In the previous week, MindWalk's average media sentiment score of 0.55 beat Mana Capital Acquisition's score of 0.00 indicating that MindWalk is being referred to more favorably in the media.
Company Overall Sentiment
MindWalk Positive
Mana Capital Acquisition Neutral
: 6.7% of MindWalk shares are owned by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are owned by institutional investors. 6.8% of MindWalk shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: Mana Capital Acquisition has lower revenue, but higher earnings than MindWalk.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MindWalk $28.08M 2.05 -$21.69M -$0.20 N/A
Mana Capital Acquisition N/A N/A N/A N/A N/A
: MindWalk presently has a consensus price target of $5.00, suggesting a potential upside of 300.00%. Given MindWalk's stronger consensus rating and higher possible upside, research analysts plainly believe MindWalk is more favorable than Mana Capital Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MindWalk
1 Sell rating(s)
1 Hold rating(s)

2 Buy rating(s)

1 Strong Buy rating(s)
2.60
Mana Capital Acquisition
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Mana Capital Acquisition	N/A	N/A	N/A

Company	Overall Sentiment
MindWalk	Positive
Mana Capital Acquisition	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$28.08M	2.05	-$21.69M	-$0.20	N/A
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

MindWalk beats Mana Capital Acquisition on 7 of the 11 factors compared between the two stocks.

Get Mana Capital Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MAAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MAAQ vs. The Competition

Export

Metric	Mana Capital Acquisition	In Vitro, In Vivo Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$15.28M	$1.50B	$4.22B	$11.77B
Dividend Yield	N/A	N/A	5.87%	5.26%
P/E Ratio	N/A	N/A	23.37	27.07
Price / Sales	N/A	261.03	156.03	73.47
Price / Cash	N/A	673.62	52.08	53.90
Price / Book	N/A	139.05	37.87	6.69
Net Income	N/A	-$21.91M	$114.66M	$332.64M
7 Day Performance	3.30%	5.78%	1.21%	2.01%
1 Month Performance	-7.84%	8.97%	5.50%	9.19%
1 Year Performance	339.87%	339.87%	18.68%	39.59%

Mana Capital Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MAAQ Mana Capital Acquisition	N/A	$1.88 +5.0%	N/A	N/A	$15.28M	N/A	N/A	1	Gap Down High Trading Volume
GRML Greenland Mines Ltd. Common Stock	0.0999 of 5 stars	$0.47 -2.9%	N/A	N/A	$58.76M	N/A	N/A	5	News Coverage Analyst Upgrade Gap Up
CUE Cue Biopharma	0.2357 of 5 stars	$17.93 +1.4%	N/A	N/A	$57.32M	$27.47M	N/A	60	Analyst Downgrade
SCLX Scilex	1.0359 of 5 stars	$6.88 +2.8%	N/A	N/A	$56.81M	$30.25M	N/A	80	News Coverage Analyst Downgrade Gap Up
MGX Metagenomi	2.0742 of 5 stars	$1.48 -1.3%	$10.00 +575.7%	N/A	$56.43M	$25.21M	N/A	236	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MAAQ) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mana Capital Acquisition (MAAQ) Competitors

MAAQ vs. GRML, CUE, SCLX, MGX, and HYFT

How does Mana Capital Acquisition compare to Greenland Mines Ltd. Common Stock?

Summary

How does Mana Capital Acquisition compare to Cue Biopharma?

Summary

How does Mana Capital Acquisition compare to Scilex?

Summary

How does Mana Capital Acquisition compare to Metagenomi?

Summary

How does Mana Capital Acquisition compare to MindWalk?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAAQ vs. The Competition

Mana Capital Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mana Capital Acquisition (MAAQ) Competitors

MAAQ vs. GRML, CUE, SCLX, MGX, and HYFT

How does Mana Capital Acquisition compare to Greenland Mines Ltd. Common Stock?

Summary

How does Mana Capital Acquisition compare to Cue Biopharma?

Summary

How does Mana Capital Acquisition compare to Scilex?

Summary

How does Mana Capital Acquisition compare to Metagenomi?

Summary

How does Mana Capital Acquisition compare to MindWalk?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAAQ vs. The Competition

Mana Capital Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools